These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24670226)

  • 1. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
    Tosti G; Cocorocchio E; Pennacchioli E; Ferrucci PF; Testori A; Martinoli C
    Expert Opin Biol Ther; 2014 Jul; 14(7):955-67. PubMed ID: 24670226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.
    di Pietro A; Tosti G; Ferrucci PF; Testori A
    Expert Opin Biol Ther; 2011 Oct; 11(10):1395-407. PubMed ID: 21801084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
    Tosti G; di Pietro A; Ferrucci PF; Testori A
    Expert Rev Vaccines; 2009 Nov; 8(11):1513-26. PubMed ID: 19863242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein-based cancer vaccines.
    Oki Y; Younes A
    Expert Rev Vaccines; 2004 Aug; 3(4):403-11. PubMed ID: 15270645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications.
    Hoos A; Levey DL
    Expert Rev Vaccines; 2003 Jun; 2(3):369-79. PubMed ID: 12903802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein vaccines against glioblastoma: from bench to bedside.
    Ampie L; Choy W; Lamano JB; Fakurnejad S; Bloch O; Parsa AT
    J Neurooncol; 2015 Jul; 123(3):441-8. PubMed ID: 26093618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccine--Antigenics.
    BioDrugs; 2002; 16(1):72-4. PubMed ID: 11909004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
    Eton O; Ross MI; East MJ; Mansfield PF; Papadopoulos N; Ellerhorst JA; Bedikian AY; Lee JE
    J Transl Med; 2010 Jan; 8():9. PubMed ID: 20109236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
    Aalamian M; Fuchs E; Gupta R; Levey DL
    Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
    Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
    Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular vaccine therapies for cancer.
    Mastrangelo MJ; Sato T; Lattime EC; Maguire HC; Berd D
    Cancer Treat Res; 1998; 94():35-50. PubMed ID: 9587681
    [No Abstract]   [Full Text] [Related]  

  • 14. Heat shock proteins (HSPs) based anti-cancer vaccines.
    Ciocca DR; Cayado-Gutierrez N; Maccioni M; Cuello-Carrion FD
    Curr Mol Med; 2012 Nov; 12(9):1183-97. PubMed ID: 22804241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Wang Y; Wang XY; Subjeck JR; Shrikant PA; Kim HL
    Br J Cancer; 2011 Feb; 104(4):643-52. PubMed ID: 21285988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy comes of age.
    Rosenberg SA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):115. PubMed ID: 16264884
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination in the immunotherapy of glioblastoma.
    Kong Z; Wang Y; Ma W
    Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock proteins gp96 as immunogens in cancer patients.
    Parmiani G; De Filippo A; Pilla L; Castelli C; Rivoltini L
    Int J Hyperthermia; 2006 May; 22(3):223-7. PubMed ID: 16754342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.
    Domingo-Musibay E; Heun JM; Nevala WK; Callstrom M; Atwell T; Galanis E; Erickson LA; Markovic SN
    Oncologist; 2017 Sep; 22(9):1026-e93. PubMed ID: 28679643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.